Pharmaceutical

Merck concludes SpringWorks acquisition for $3.4bn

Merck KGaA has concluded the previously announced acquisition of SpringWorks Therapeutics for an enterprise value of €3bn ($3.4bn).

Jul 3, 2025 - 06:00
Merck concludes SpringWorks acquisition for $3.4bn
Merck KGaA has concluded the previously announced acquisition of SpringWorks Therapeutics for an enterprise value of €3bn ($3.4bn).
Read the original article

Tags:

Previous Article

Vertex wins European approval for Alyftrek, bolstering cystic fibrosis stronghold

Next Article

Cell and gene therapy: The vital role of logistics

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

CRISPR is about to make history. Here’s the 5-minute rundown of what to expect

CRISPR is about to make history. Here’s the 5-minute ru...

Dec 9, 2023

STAT+: RayzeBio co-founder, industry veterans launch new biotech VC with $310 million

STAT+: RayzeBio co-founder, industry veterans launch ne...

Feb 7, 2024

MediLink and Roche partner on cancer drug development

MediLink and Roche partner on cancer drug development

Jan 3, 2024